The safety and efficacy of short-term budesonide delivered via mucosal atomization device for chronic rhinosinusitis without nasal polyposis

International Forum of Allergy and Rhinology

Volumn 4, Issue 5, 2014, Pages 397-402

  Thamboo, Andrew ^a   Manji, Jamil ^a   Szeitz, András ^a   Santos, Rachelle Dar ^a   Hathorn, Iain ^a   Gan, Eng Cern ^a   Alsaleh, Saad ^a   Javer, Amin R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Budesonide; Chronic rhinosinusitis; Irrigations; Mucosal atomization device; Quality of life; Safety

Indexed keywords

BUDESONIDE; CORTICOTROPIN; HYDROCORTISONE; ANTIINFLAMMATORY AGENT;

ADRENAL SUPPRESSION; ARTICLE; CHRONIC RHINOSINUSITIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MALE; MUCOSAL ATOMIZATION DEVICE; NEBULIZER; NOSE POLYP; PRIORITY JOURNAL; PROVOCATION TEST; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TANDEM MASS SPECTROMETRY; CANADA; CHRONIC DISEASE; COMPLICATION; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; MUCOSAL ADMINISTRATION; PROSPECTIVE STUDY; RHINITIS; SINUSITIS; TIME; TREATMENT OUTCOME; UTILIZATION;

ADMINISTRATION, MUCOSAL; ANTI-INFLAMMATORY AGENTS; BUDESONIDE; CANADA; CHRONIC DISEASE; FEMALE; HUMANS; HYDROCORTISONE; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; NASAL POLYPS; NEBULIZERS AND VAPORIZERS; PITUITARY-ADRENAL SYSTEM; PROSPECTIVE STUDIES; QUALITY OF LIFE; RHINITIS; SINUSITIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899623635     PISSN: 20426976     EISSN: 20426984     Source Type: Journal    
DOI: 10.1002/alr.21280     Document Type: Article

References (41)

1. Poetker DM, Reh DD. A comprehensive review of the adverse effects of systemic corticosteroids. Otolaryngol Clin North Am. 2010;43:753-768.
2. Pujols L, Mullol J, Torrego A, Picado C. Glucocorticoid receptors in human airways. Allergy. 2004;59:1042-1052.
3. Yun CB, Lee BH, Jang TJ. Expression of glucocorticoid receptors and cyclooxygenase-2 in nasal polyps from nonallergic patients. Ann Otol Rhinol Laryngol. 2002;111:61-67.
4. Desrosiers M, Evans GA, Keith PK, et al. Canadian clinical practice guidelines for acute and chronic rhinosinusitis. J Otolaryngol Head Neck Surg. 2011;40(Suppl 2):S99-S193.
5. Vogeser M, Seger C. A decade of HPLC-MS/MS in the routine clinical laboratory-goals for further developments. Clin Biochem. 2008;41:649-662.
6. Xu RN, Fan L, Rieser MJ, El-Shourbagy TA. Recent advances in high-throughput quantitative bioanalysis by LC-MS/MS. J Pharm Biomed Anal. 2007;44:342-355.
7. Turpeinen U, Stenman UH. Determination of urinary free cortisol by liquid chromatography-tandem mass spectrometry. Scand J Clin Lab Invest. 2003;63:143-150.
8. Szeitz A., et al., Validated assay for the simultaneous determination of cortisol and budesonide in human plasma using ultra high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2013;90C: p. 198-206.
9. Hopkins C, Gillett S, Slack R, Lund VJ, Browne JP. Psychometric validity of the 22-item Sinonasal Outcome Test. Clin Otolaryngol. 2009;34:447-454.
10. Longui CA, Vottero A, Harris AG, Chrousos GP. Plasma cortisol responses after intramuscular corticotropin 1-24 in healthy men. Metabolism. 1998;47:1419-1422.
11. Liang J, Strong EB. Examining the safety of prednisolone acetate 1% nasal spray for treatment of nasal polyposis. Int Forum Allergy Rhinol. 2012;2:126-129.
12. Howland WC 3rd. Fluticasone propionate: topical or systemic effects? Clin Exp Allergy. 1996;26(Suppl 3):18-22.
13. LaForce CF, Dockhorn RJ, Findlay SR, et al. Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents. J Fam Pract. 1994;38:145-152.
14. Bachert C, Lukat KF, Lange B. Effect of intranasal fluticasone propionate and triamcinolone acetonide on basal and dynamic measures of hypothalamic-pituitary-adrenal-axis activity in healthy volunteers. Clin Exp Allergy. 2004;34:85-90.
15. Galant SP, Melamed IR, Nayak AS, et al. Lack of effect of fluticasone propionate aqueous nasal spray on the hypothalamic-pituitary-adrenal axis in 2- and 3-year-old patients. Pediatrics. 2003;112:96-100.
16. Skoner DP, Gentile D, Angelini B, Kane R, Birdsall D, Banerji D. The effects of intranasal triamcinolone acetonide and intranasal fluticasone propionate on short-term bone growth and HPA axis in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2003;90:56-62.
17. Vargas R, Dockhorn RJ, Findlay SR, Korenblat PE, Field EA, Kral KM. Effect of fluticasone propionate aqueous nasal spray versus oral prednisone on the hypothalamic-pituitary-adrenal axis. J Allergy Clin Immunol. 1998;102:191-197.
18. Welch MJ, Bronsky E, Findlay S, et al. Long-term safety of triamcinolone acetonide nasal aerosol for the treatment of perennial allergic rhinitis. Clin Ther. 1994;16:253-262.
19. Brannan MD, Herron JM, Affrime MB. Safety and tolerability of once-daily mometasone furoate aqueous nasal spray in children. Clin Ther. 1997;19:1330-1339.
20. Schenkel EJ, Skoner DP, Bronsky EA, et al. Absence of growth retardation in children with perennial allergic rhinitis after one year of treatment with mometasone furoate aqueous nasal spray. Pediatrics. 2000;105:E22.
21. Nayak AS, Settipane GA, Pedinoff A, et al. Effective dose range of mometasone furoate nasal spray in the treatment of acute rhinosinusitis. Ann Allergy Asthma Immunol. 2002;89:271-278.
22. Tripathy I, Levy A, Ratner P, Clements D, Wu W, Philpot E. HPA axis safety of fluticasone furoate nasal spray once daily in children with perennial allergic rhinitis. Pediatr Allergy Immunol. 2009;20:287-294.
23. Meltzer EO, Tripathy I, Máspero JF, Wu W, Philpot E. Safety and tolerability of fluticasone furoate nasal spray once daily in paediatric patients aged 6-11 years with allergic rhinitis: subanalysis of three randomized, double-blind, placebo-controlled, multicentre studies. Clin Drug Investig. 2009;29:79-86.
24. Patel D, Ratner P, Clements D, Wu W, Faris M, Philpot E. Lack of effect on adult and adolescent hypothalamic-pituitary-adrenal axis function with use of fluticasone furoate nasal spray. Ann Allergy Asthma Immunol. 2008;100:490-496.
25. Synnerstad B, Lindqvist N. A clinical comparison of intranasal budesonide with beclomethasone dipropionate for perennial non-allergic rhinitis: a 12 month study. Br J Clin Pract. 1996;50:363-366.
26. Kokron CM, Castro AS, Solé D, Naspitz CK. Lysine-vasopressin in the evaluation of the hypothalamic-pituitary-adrenal axis in children with allergic rhinitis treated with intranasal beclomethasone dipropionate or oral prednisone. J Investig Allergol Clin Immunol. 1997;7:51-56.
27. Skoner DP, Rachelefsky GS, Meltzer EO, et al. Detection of growth suppression in children during treatment with intranasal beclomethasone dipropionate. Pediatrics. 2000;105:E23.
28. Ratner PH, Miller SD, Hampel FC Jr, Melchior A, Dunbar SA, Tantry SK. Once-daily treatment with beclomethasone dipropionate nasal aerosol does not affect hypothalamic-pituitary-adrenal axis function. Ann Allergy Asthma Immunol. 2012;109:336-341.
29. Fowler PD, Gazis AG, Page SR, Jones NS. A randomized double-blind study to compare the effects of nasal fluticasone and betamethasone on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clin Otolaryngol Allied Sci. 2002;27:489-493.
30. Gazis AG, Homer JJ, Henson DB, Page SR, Jones NS. The effect of six weeks topical nasal betamethasone drops on the hypothalamo-pituitary-adrenal axis and bone turnover in patients with nasal polyposis. Clin Otolaryngol Allied Sci. 1999;24:495-498.
31. Pipkorn U, Pukander J, Suonpää J, Mäkinen J, Lindqvist N. Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study. Clin Allergy. 1988;18:253-259.
32. Sachanandani NS, Piccirillo JF, Kramper MA, Thawley SE, Vlahiotis A. The effect of nasally administered budesonide respules on adrenal cortex function in patients with chronic rhinosinusitis. Arch Otolaryngol Head Neck Surg. 2009;135:303-307.
33. Kim KT, Rabinovitch N, Uryniak T, Simpson B, O'Dowd L, Casty F. Effect of budesonide aqueous nasal spray on hypothalamic-pituitary-adrenal axis function in children with allergic rhinitis. Ann Allergy Asthma Immunol. 2004;93:61-67.
34. Lindqvist N, Balle VH, Karma P, et al. Long-term safety and efficacy of budesonide nasal aerosol in perennial rhinitis. A 12-month multicentre study. Allergy. 1986;41:179-186.
35. Agertoft L, Wolthers OD, Fuglsang G, Pedersen S. Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Pediatr Allergy Immunol. 1993;4:152-156.
36. Bhalla RK, Payton K, Wright ED. Safety of budesonide in saline sinonasal irrigations in the management of chronic rhinosinusitis with polyposis: lack of significant adrenal suppression. J Otolaryngol Head Neck Surg. 2008;37:821-825.
37. Welch KC, Thaler ER, Doghramji LL, Palmer JN, Chiu AG. The effects of serum and urinary cortisol levels of topical intranasal irrigations with budesonide added to saline in patients with recurrent polyposis after endoscopic sinus surgery. Am J Rhinol Allergy. 2010;24:26-28.
38. Wihl JA, Andersson KE, Johansson SA. Systemic effects of two nasally administered glucocorticosteroids. Allergy. 1997;52:620-626.
39. Benninger MS, Ahmad N, Marple BF. The safety of intranasal steroids. Otolaryngol Head Neck Surg. 2003;129:739-750.
40. Cannady SB, Batra PS, Citardi MJ, Lanza DC. Comparison of delivery of topical medications to the paranasal sinuses via "vertex-to-floor" position and atomizer spray after FESS. Otolaryngol Head Neck Surg. 2005;133:735-740.
41. Habib AR, Thamboo A, Manji J, et al. The effect of head position on the distribution of topical nasal medication using the Mucosal Atomization Device: a cadaver study. Int Forum Allergy Rhinol. 2013;3:958-962.